Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + nab-paclitaxel + pembrolizumab + mirabegron
- Development stage
- Unknown
- Lead developer
- Obstetrics and Gynecology Hospital of Fudan University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This experimental combination regimen is being investigated by the Obstetrics & Gynecology Hospital of Fudan University for the treatment of recurrent ovarian cancer. The regimen integrates standard-of-care chemotherapy (either weekly paclitaxel or nanoparticle albumin-bound paclitaxel) with the PD-1 checkpoint inhibitor pembrolizumab and the beta-3 adrenergic receptor agonist mirabegron. Paclitaxel and nab-paclitaxel are microtubule-stabilizing agents that interfere with mitosis, leading to cell death. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby revitalizing the anti-tumor T-cell response. Mirabegron, traditionally used for overactive bladder, is included in this oncology setting based on research suggesting that beta-3 adrenergic signaling modulation can influence the tumor microenvironment and potentially enhance the efficacy of immunotherapy and chemotherapy.
- Other names
- Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and MirabegronPaclitaxel/Nab-Paclitaxel + Pembrolizumab + Mirabegron
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ADRB3 (β3)
Beyond the preview
Go deeper on paclitaxel + nab-paclitaxel + pembrolizumab + mirabegron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + nab-paclitaxel + pembrolizumab + mirabegron.